OrbiMed’s KalVista Pharmaceuticals KALV Stock Holding History

OrbiMed’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.9M	Sell	94,400 -288,000	-75%	-$4.64M	0.04%	107
2025 Q4	$6.18M	Buy	+382,400	New	+$5.06M	0.13%	89
2022 Q4	–	Sell	-1,042,000	Closed	-$15.1K	–	123
2022 Q3	$15.1K	Buy	1,042,000 +856,600	+462%	+$12M	0.28%	74
2022 Q2	$1.82K	Buy	+185,400	New	+$2.05M	0.03%	133
2020 Q2	–	Sell	-420,641	Closed	-$3.22M	–	144
2020 Q1	$3.22M	Buy	420,641 +260,100	+162%	+$3.51M	0.05%	116
2019 Q4	$2.86M	Buy	160,541 +121,808	+314%	+$1.59M	0.04%	114
2019 Q3	$449K	Buy	+38,733	New	+$626K	0.01%	114
2019 Q2	–	Sell	-90,500	Closed	-$2.59M	–	134
2019 Q1	$2.59M	Buy	+90,500	New	+$1.96M	0.04%	115

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed's KALV Position: Q1 2026 in Review

OrbiMed reduced its KalVista Pharmaceuticals (KALV) stake by 75% in Q1 2026, selling an estimated $4.64M and leaving 94,400 shares worth $1.9M. The position accounts for 0.04% of the portfolio, ranked #107.

OrbiMed first reported a position in KALV in Q1 2019 and has held it in 8 quarters since. The position peaked at $6.18M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

OrbiMed held 94,400 shares of KalVista Pharmaceuticals worth $1.9M as of Q1 2026.
OrbiMed sold 288,000 KalVista Pharmaceuticals shares in Q1 2026, an estimated $4.64M.
KalVista Pharmaceuticals made up 0.04% of OrbiMed's portfolio in Q1 2026, its #107 holding.
OrbiMed first reported a position in KalVista Pharmaceuticals in Q1 2019 and has held it in 8 quarters since.
OrbiMed's KalVista Pharmaceuticals position peaked at $6.18M in Q4 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.